NS Partners Ltd Has $19.86 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

NS Partners Ltd grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,310 shares of the company’s stock after acquiring an additional 761 shares during the period. NS Partners Ltd’s holdings in IDEXX Laboratories were worth $19,860,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IDXX. Acadian Asset Management LLC lifted its position in IDEXX Laboratories by 83.0% during the first quarter. Acadian Asset Management LLC now owns 4,219 shares of the company’s stock worth $2,276,000 after acquiring an additional 1,913 shares during the last quarter. Edgestream Partners L.P. increased its holdings in shares of IDEXX Laboratories by 124.6% during the first quarter. Edgestream Partners L.P. now owns 2,035 shares of the company’s stock worth $1,099,000 after purchasing an additional 1,129 shares during the period. O Shaughnessy Asset Management LLC increased its holdings in shares of IDEXX Laboratories by 10.2% during the first quarter. O Shaughnessy Asset Management LLC now owns 6,876 shares of the company’s stock worth $3,713,000 after purchasing an additional 639 shares during the period. Clearbridge Investments LLC increased its holdings in shares of IDEXX Laboratories by 3.5% during the first quarter. Clearbridge Investments LLC now owns 44,321 shares of the company’s stock worth $23,930,000 after purchasing an additional 1,479 shares during the period. Finally, Lake Street Advisors Group LLC increased its holdings in shares of IDEXX Laboratories by 61.4% during the first quarter. Lake Street Advisors Group LLC now owns 1,504 shares of the company’s stock worth $812,000 after purchasing an additional 572 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $416.34 on Wednesday. The firm has a market cap of $34.09 billion, a PE ratio of 40.15, a price-to-earnings-growth ratio of 3.67 and a beta of 1.36. The firm’s fifty day moving average is $465.52 and its 200-day moving average is $481.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 52 week low of $404.74 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.53 earnings per share. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on IDXX shares. BTIG Research started coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Barclays decreased their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.